Impairment of skin barrier function via cholinergic signal transduction in a dextran sulphate sodium-induced colitis mouse model

Experimental Dermatology

Volumn 24, Issue 10, 2015, Pages 779-784

  Yokoyama, Satoshi ^a   Hiramoto, Keiichi ^a   Koyama, Mayu ^a   Ooi, Kazuya ^a  

^a SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Acetylcholine receptor; Colitis; Mast cell; Skin hydration; Transepidermal water loss

Indexed keywords

ACETYLCHOLINE; DEXTRAN SULFATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MUSCARINIC RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ATROPINE; ENZYME INHIBITOR; HEXAMETHONIUM; MONOCLONAL ANTIBODY; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; NITRIC ACID DERIVATIVE; NITROGEN DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; EXPERIMENTAL COLITIS; HISTOLOGY; MALE; MAST CELL; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKIN INJURY; SKIN WATER LOSS; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL COUNT; CHEMICALLY INDUCED; COLITIS; COLON; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; IMMUNOLOGY; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN DISEASES; THERMOREGULATION; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ATROPINE; CELL COUNT; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HEXAMETHONIUM; INTERLEUKIN-6; MALE; MAST CELLS; MICE; MUSCARINIC ANTAGONISTS; NICOTINIC ANTAGONISTS; NITRATES; NITRIC OXIDE SYNTHASE TYPE II; NITROGEN DIOXIDE; ORGAN SIZE; RECEPTORS, MUSCARINIC; SIGNAL TRANSDUCTION; SKIN DISEASES; SKIN PHYSIOLOGICAL PHENOMENA; TUMOR NECROSIS FACTOR-ALPHA; WATER LOSS, INSENSIBLE; WEIGHT LOSS;

EID: 84942294521     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12775     Document Type: Article

References (41)

1. Norman R A. Dermatol Ther 2003: 6: 254-259.
2. Kim D W, Park J Y, Na G Y et al. Int J Dermatol 2006: 45: 698-701.
3. Tagami H, Kobayashi H, O'Goshi K et al. J Cosmet Dermatol 2006: 5: 140-149.
4. Yokoyama S, Hiramoto K, Koyama M et al. Exp Dermatol 2014: 23: 659-663.
5. Park T H, Park C H, Ha S K et al. Nephrol Dial Transplant 1995: 10: 2269-2273.
6. Niederau C, Lange S, Frühauf M et al. Liver Int 2008: 28: 659-666.
7. Sakai S, Kikuchi K, Satoh J et al. Br J Dermatol 2005: 153: 319-323.
8. Cummings J H. Gut 1975: 16: 323-329.
9. Fakhoury M, Negrulj R, Mooranian A et al. J Inflamm Res 2014: 23: 113-120.
10. Murthy S K, Nguyen G C. Am J Gastroenterol 2011: 106: 713-718.
11. Twig G, Zandman-Goddard G, Szyper-Kravitz M et al. Ann N Y Acad Sci 2005: 1051: 166-173.
12. Huang B L, Chandra S, Shih D Q. Front Physiol 2012: 3: 13.
13. Williams H, Walker D, Orchard T R. Curr Gastroenterol Rep 2008: 10: 597-603.
14. Reimund J M, Wittersheim C, Dumont S et al. Gut 1996: 39: 684-689.
15. Schottelius A J, Moldawer L L, Dinarello C A et al. Exp Dermatol 2004: 13: 193-222.
16. Krieglstein C F, Cerwinka W H, Laroux F S et al. J Exp Med 2001: 194: 1207-1218.
17. Orita K, Hiramoto K, Kobayashi H et al. Exp Dermatol 2011: 20: 911-914.
18. Nishimura T, Andoh A, Hashimoto T et al. J Clin Biochem Nutr 2010: 46: 105-110.
19. Imai A, Nabe T, Mizutani N et al. Eur J Pharmacol 2001: 423: 63-70.
20. Barel A O, Clarys P. Skin Pharmacol 1995: 8: 186-195.
21. Berardesca E. European Group for Efficacy Measurements on Cosmetics and Other Topical Products (EEMCO). Skin Res Technol 1997: 3: 126-132.
22. Breese E J, Michie C A, Nicholls S W et al. Gastroenterology 1994: 106: 1455-1466.
23. Schreiber O, Petersson J, Waldén T et al. PLoS One 2013: 8: e71843.
24. Wajant H, Pfizenmaier K, Scheurich P. Cell Death Differ 2003: 10: 45-65.
25. Wajant H. Results Probl Cell Differ 2009: 49: 1-15.
26. Holtmann M H, Douni E, Schütz M et al. Eur J Immunol 2002: 32: 3142-3151.
27. Mizoguchi E, Mizoguchi A, Takedatsu H et al. Gastroenterology 2002: 122: 134-144.
28. Kondo S, Sauder D N. Eur J Immunol 1997: 27: 1713-1718.
29. Mori L, Iselin S, De Libero G et al. J Immunol 1996: 157: 3178-3182.
30. Kassiotis G, Kollias G. J Exp Med 2001: 193: 427-434.
31. Taniuchi S, Kojima T, Hara Mt K et al. Allergy 2001: 56: 693-695.
32. Ormerod A D, Weller R, Copeland P et al. Arch Dermatol Res 1998: 290: 3-8.
33. Radosa J, Dyck W, Goerdt S et al. Exp Dermatol 2011: 20: 677-679.
34. Blandina P, Fantozzi R, Mannaioni P F et al. J Physiol 1980: 301: 281-293.
35. Koarai A, Traves S L, Fenwick P S et al. Eur Respir J 2012: 39: 698-704.
36. Buchli R, Ndoye A, Rodriguez J G et al. J Cell Biochem 1999: 74: 264-277.
37. Grando S A. Exp Dermatol 2006: 15: 265-282.
38. Ito T, Smrž D, Jung M Y et al. J Immunol 2012: 188: 5428-5437.
39. Tanaka S. Expert Opin Ther Targets 2010: 14: 31-43.
40. Kurashima Y, Amiya T, Fujisawa K et al. Immunity 2014: 40: 530-541.
41. Wulff B C, Wilgus T A. Exp Dermatol 2013: 22: 507-510.